203 related articles for article (PubMed ID: 36536047)
1. Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer.
Liu Z; Hayashi H; Matsumura K; Ogata Y; Sato H; Shiraishi Y; Uemura N; Miyata T; Higashi T; Nakagawa S; Mima K; Imai K; Baba H
Br J Cancer; 2023 Mar; 128(5):844-856. PubMed ID: 36536047
[TBL] [Abstract][Full Text] [Related]
2. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma.
Zhao C; Gong J; Bai Y; Yin T; Zhou M; Pan S; Liu Y; Gao Y; Zhang Z; Shi Y; Zhu F; Zhang H; Wang M; Qin R
Cell Death Differ; 2023 Jan; 30(1):1-15. PubMed ID: 35906484
[TBL] [Abstract][Full Text] [Related]
3. Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis.
Morvaridi S; Dhall D; Greene MI; Pandol SJ; Wang Q
Sci Rep; 2015 Nov; 5():16759. PubMed ID: 26567630
[TBL] [Abstract][Full Text] [Related]
4. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
5. Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling.
Gopal U; Mowery Y; Young K; Pizzo SV
J Biol Chem; 2019 Sep; 294(38):13939-13952. PubMed ID: 31358620
[TBL] [Abstract][Full Text] [Related]
6. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
[TBL] [Abstract][Full Text] [Related]
7. Loss of Arid1a and Pten in Pancreatic Ductal Cells Induces Intraductal Tubulopapillary Neoplasm via the YAP/TAZ Pathway.
Fukunaga Y; Fukuda A; Omatsu M; Namikawa M; Sono M; Masuda T; Araki O; Nagao M; Yoshikawa T; Ogawa S; Hiramatsu Y; Muta Y; Tsuda M; Maruno T; Nakanishi Y; Ferrer J; Tsuruyama T; Masui T; Hatano E; Seno H
Gastroenterology; 2022 Aug; 163(2):466-480.e6. PubMed ID: 35483445
[TBL] [Abstract][Full Text] [Related]
8. lncRNA
Li N; Yang G; Luo L; Ling L; Wang X; Shi L; Lan J; Jia X; Zhang Q; Long Z; Liu J; Hu W; He Z; Liu H; Liu W; Zheng G
Clin Cancer Res; 2020 Apr; 26(7):1736-1748. PubMed ID: 31831555
[TBL] [Abstract][Full Text] [Related]
9. The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level.
Thongon N; Castiglioni I; Zucal C; Latorre E; D'Agostino V; Bauer I; Pancher M; Ballestrero A; Feldmann G; Nencioni A; Provenzani A
Oncotarget; 2016 May; 7(18):26551-66. PubMed ID: 27034169
[TBL] [Abstract][Full Text] [Related]
10. YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells.
Yuan Y; Li D; Li H; Wang L; Tian G; Dong Y
Mol Med Rep; 2016 Jan; 13(1):237-42. PubMed ID: 26572166
[TBL] [Abstract][Full Text] [Related]
11. The Hippo Signaling Pathway in Pancreatic Cancer.
Ansari D; Ohlsson H; Althini C; Bauden M; Zhou Q; Hu D; Andersson R
Anticancer Res; 2019 Jul; 39(7):3317-3321. PubMed ID: 31262852
[TBL] [Abstract][Full Text] [Related]
12. MiR-33a Controls hMSCS Osteoblast Commitment Modulating the Yap/Taz Expression Through EGFR Signaling Regulation.
Costa V; Carina V; Raimondi L; De Luca A; Bellavia D; Conigliaro A; Salamanna F; Alessandro R; Fini M; Giavaresi G
Cells; 2019 Nov; 8(12):. PubMed ID: 31771093
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of yes-associated protein/YAP and transcriptional coactivator with PDZ-binding motif/TAZ activates intestinal fibroblasts to promote intestinal obstruction in Crohn's disease.
Ou W; Xu W; Liu F; Guo Y; Huang Z; Feng T; Liu CY; Du P
EBioMedicine; 2021 Jul; 69():103452. PubMed ID: 34186485
[TBL] [Abstract][Full Text] [Related]
14. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition.
Diepenbruck M; Waldmeier L; Ivanek R; Berninger P; Arnold P; van Nimwegen E; Christofori G
J Cell Sci; 2014 Apr; 127(Pt 7):1523-36. PubMed ID: 24554433
[TBL] [Abstract][Full Text] [Related]
15. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
[TBL] [Abstract][Full Text] [Related]
16. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.
Li H; Jiang W; Liu XN; Yuan LY; Li TJ; Li S; Xu SS; Zhang WH; Gao HL; Han X; Wang WQ; Wu CT; Yu XJ; Xu HX; Liu L
Oncogene; 2020 Sep; 39(36):5825-5838. PubMed ID: 32753651
[TBL] [Abstract][Full Text] [Related]
17. Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer.
Ando T; Charindra D; Shrestha M; Umehara H; Ogawa I; Miyauchi M; Takata T
Oncogene; 2018 Jan; 37(2):263-270. PubMed ID: 28925394
[TBL] [Abstract][Full Text] [Related]
18. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
[TBL] [Abstract][Full Text] [Related]
19. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma.
Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H
Front Oncol; 2021; 11():700315. PubMed ID: 34395269
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions.
Jiang Z; Zhou C; Cheng L; Yan B; Chen K; Chen X; Zong L; Lei J; Duan W; Xu Q; Li X; Wang Z; Ma Q; Ma J
J Exp Clin Cancer Res; 2018 Mar; 37(1):69. PubMed ID: 29587800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
